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The enigma of young age
Breast cancer in very young patients has traditionally been
considered as particularly aggressive and associated with a poor
prognosis. The negative prognostic impact of young age has
been substantiated in numerous studies of clinical databases
[1–4] including a recent population-based analysis of patients
with stage I breast cancer: After adjusting for tumor size,
histological grade, estrogen receptor (ER) expression, and year
of diagnosis, the age at diagnosis was still a significant predictor
with each year younger than 45 years adding a relative 5% to
the risk of death from breast cancer [5]. The distinction between
young and ‘very young’ premenopausal patients is fuzzy but
most investigators who chose to dichotomize their analysis used
an age limit of 35–40 years.
It appears obvious that age by itself cannot explain the less
favorable outlook of young patients with breast cancer but
rather that age is a surrogate for biological features that
determine the more aggressive behavior of breast cancers in
young women. Indeed, it is a common feature of most studies
investigating known prognostic factors in young women to find
higher proportions of poorly differentiated, rapidly
proliferating, ER- and progesterone receptor (PgR)-negative
tumors that tend to be larger and to involve regional lymph
nodes [3, 6, 7]; similarly, bone marrow micrometastases,
another negative prognostic factor, are observed more
frequent in young patients [8]. In some of these analyses,
multivariate modeling eliminated age as an independent
prognostic factor [6, 9] but in many others the known
biological factors did not completely explain the higher
likelihood of local [10] and distant recurrence conferred by
young age [3, 4, 11].
The interpretation of such retrospective data is confounded
by adjuvant therapies that modify the natural course of breast
cancer and by temporal changes in the use of such therapies. For
instance, the gradual reduction of breast cancer mortality from
1988 to 1997 observed in a recent analysis of SEER data for
patients younger that 45 years with stage I breast cancer [5]
could result from increased use of adjuvant systemic therapies in
the same time period. Indeed, the historically poor prognosis
may be related to inadequate therapy as illustrated by data from
Denmark on the basis of a population of patients who were
diagnosed with breast cancer from 1978 to 1996. Young
patients who did not receive adjuvant systemic therapy due to
apparent low-risk disease had a much higher probability of
recurrence than older patients with otherwise similar
characteristics. This negative impact of young age was not
observed in patients with higher risk breast cancer who did
receive adjuvant systemic therapy. While the use of
chemotherapy without hormonal therapy would be considered
substandard today, the omission of systemic therapy for very
young, seemingly low-risk patients might have contributed to
the poor prognosis [12].
Adjuvant chemotherapy may act on at least two general
pathways: direct cytotoxic effects in cancer cells and endocrine
effects. While cytotoxicity is likely the main mechanism of
action in breast cancers that do not express ER and PgR, the
suppression of ovarian function by chemotherapy may be the
principal mode of action in ER-positive disease: continuing
menses is a strong predictor of an unfavorable outcome both
after CMF-based [13–16] and after anthracycline-containing
chemotherapy [17]. Obviously, the probability of developing
amenorrhea depends on the age of the patient and on the
regimen used [18]; it is therefore not possible to separately
assess the effects of age and of amenorrhea. However, the
suppression of ovarian function for at least 2 years has been
found to be at least as effective as CMF- and epirubicin-based
chemotherapy without endocrine therapy in at least eight
randomized controlled trials [19]; none of these trials reported
differential effects of endocrine or chemotherapy by age,
although some confirmed an inferior prognosis for very young
patients [15].
Tamoxifen reduces the risk of relapse and death from
ER-positive breast cancer; its efficacy does not depend on
age and is not diminished by prior chemotherapy [20–22].
Given these complexities, what does the paper reported by
authors of the European Institute of Oncology add? Colleoni
and et al. [23] have analyzed their prospectively collected
database of 841 premenopausal patients treated at their
institution for node-negative breast cancer, and they compared
the prognostic factors, treatments, and outcomes between very
young (below 35 years of age) and older premenopausal
patients. As compared to previously reported series, their data
are derived from a relatively recent period such that the
treatments used are still relevant for today’s practice.
Unfavorable prognostic factors were more common in tumors
of very young patients as expected from other patient series.
Despite a relatively standardized therapeutic approach including
hormonal therapy for the very young patients with ER-positive
tumors, the very young patients were still found to have
a significantly higher risk of relapse and death than older
patients. This was especially true for patients with ER-positive
tumors who did not receive appropriate adjuvant therapy; this
observation, while biologically plausible, is based on a subgroup
of 18 patients, such that firm conclusions cannot be drawn.
Multivariate analyses of survival did not eliminate age as
a prognostic factor despite adjusting for tumor size, vascular
invasion, proliferation fraction, ER and PgR, and
overexpression of HER-2 protein.
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Thus, even in a relatively recent population of patients with
node-negative early breast cancer that was diagnosed and
treated in a reasonably short time period at a single
institution, the typical prognostic factors did not fully explain
the negative impact of young age. Recently, the development
of high-throughput molecular methods has enabled
researchers to establish prognostic RNA expression profiles.
Several groups have demonstrated that such profiles were able
to predict the outcome of breast cancer more accurately than
traditional prognostic factors [24–26]. Of particular interest
in this context is the analysis of van de Vijver et al. [25]: The
proportion of patients with a poor-prognosis gene signature
was inversely correlated with age; such signatures were most
frequently observed among the youngest women. While
young age was a negative prognostic factor on univariate
analysis, it was not an independent factor in a multivariate
analysis including the gene signature. While similar results
have been reported by using the more traditional Nottingham
prognostic score [27], the molecular approach offers the
potential to investigate the specific mechanisms of
carcinogenesis leading to breast cancer at a very young age
and to develop therapies that target the involved molecular
aberrations. In this context, a recent publication from the
Amsterdam group deserves to be mentioned as an example:
Dai et al. [28] demonstrated in an analysis of 311 breast
cancer samples that while there is on average a positive
correlation of ER expression with age, there is
a subpopulation of young women whose cancers express
a particularly high level of ER for their age. The cancers of this
subgroup have a poor prognosis and are characterized by
a strong expression of cell cycle-associated genes [28]. While
these findings cannot yet be translated directly into
therapeutic recommendations, they offer a first molecular clue
as to why very young patients with ER-positive breast cancer
tend to have a worse prognosis than patients with ER-negative
disease as observed by Colleoni et al. [23] in patients who did
receive appropriate therapy as well as by other groups in
young patients who were treated with chemotherapy but
without adjuvant hormonal treatments [29].
The question why breast cancers in very young patients, in
particular below the age of 35–40, tend to carry a poorer
prognosis than in older patients remains unanswered; as
a logical consequence, there are no therapies that are specifically
tailored to the characteristics of such tumors with the exception
of conventional hormonal agents for patients with ER- or PgR-
positive breast cancer. Studies with conventional prognostic
factors have exhausted their potential, and any progress will
be based on the investigation of molecular events leading to
and promoting the development of breast cancer. In the
meantime, the best therapy for very young patients is in the
framework of a clinical study such as SOFT, TEXT, or
PERCHE (http://www.ibcsg.org).
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